2:23 PM
 | 
Aug 09, 2018
 |  BC Extra  |  Company News

Second Vertex drug caught in CF standoff

NICE's suspension of its review of Symkevi tezacaftor/ivacaftor on Thursday marks the latest delay of access in England and Wales to cystic fibrosis drugs from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX).

NICE suspended its review after the company did not provide an evidence submission, according to the committee's website. It also canceled plans to discuss Symkevi's appraisal at a Nov. 8 meeting.

EMA's CHMP recommended approval of Symkevi last month.

In a statement emailed to BioCentury, David Ramsden, chief executive of the U.K.-based Cystic Fibrosis Trust, said Vertex not submitting evidence to NICE, "is awful news for thousands of people in the U.K....

Read the full 492 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >